Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Crystallographic fragment screening and structure-based optimization yields a new class of influenza endonuclease inhibitors.

Bauman JD, Patel D, Baker SF, Vijayan RS, Xiang A, Parhi AK, Martínez-Sobrido L, LaVoie EJ, Das K, Arnold E.

ACS Chem Biol. 2013 Nov 15;8(11):2501-8. doi: 10.1021/cb400400j. Epub 2013 Sep 13.

2.

Identification of influenza endonuclease inhibitors using a novel fluorescence polarization assay.

Baughman BM, Jake Slavish P, DuBois RM, Boyd VA, White SW, Webb TR.

ACS Chem Biol. 2012 Mar 16;7(3):526-34. doi: 10.1021/cb200439z. Epub 2012 Jan 19.

3.

Phenyl substituted 3-hydroxypyridin-2(1H)-ones: inhibitors of influenza A endonuclease.

Parhi AK, Xiang A, Bauman JD, Patel D, Vijayan RS, Das K, Arnold E, Lavoie EJ.

Bioorg Med Chem. 2013 Nov 1;21(21):6435-46. doi: 10.1016/j.bmc.2013.08.053. Epub 2013 Sep 4.

PMID:
24055080
4.

Investigation of the salicylaldehyde thiosemicarbazone scaffold for inhibition of influenza virus PA endonuclease.

Rogolino D, Bacchi A, De Luca L, Rispoli G, Sechi M, Stevaert A, Naesens L, Carcelli M.

J Biol Inorg Chem. 2015 Oct;20(7):1109-21. doi: 10.1007/s00775-015-1292-0. Epub 2015 Sep 1.

PMID:
26323352
5.

Structural analysis of specific metal chelating inhibitor binding to the endonuclease domain of influenza pH1N1 (2009) polymerase.

Kowalinski E, Zubieta C, Wolkerstorfer A, Szolar OH, Ruigrok RW, Cusack S.

PLoS Pathog. 2012;8(8):e1002831. doi: 10.1371/journal.ppat.1002831. Epub 2012 Aug 2.

6.

An integrated biological approach to guide the development of metal-chelating inhibitors of influenza virus PA endonuclease.

Stevaert A, Nurra S, Pala N, Carcelli M, Rogolino D, Shepard C, Domaoal RA, Kim B, Alfonso-Prieto M, Marras SA, Sechi M, Naesens L.

Mol Pharmacol. 2015 Feb;87(2):323-37. doi: 10.1124/mol.114.095588. Epub 2014 Dec 4.

7.

Bunyaviridae RNA polymerases (L-protein) have an N-terminal, influenza-like endonuclease domain, essential for viral cap-dependent transcription.

Reguera J, Weber F, Cusack S.

PLoS Pathog. 2010 Sep 16;6(9):e1001101. doi: 10.1371/journal.ppat.1001101.

8.

Design of the influenza virus inhibitors targeting the PA endonuclease using 3D-QSAR modeling, side-chain hopping, and docking.

Yan Z, Zhang L, Fu H, Wang Z, Lin J.

Bioorg Med Chem Lett. 2014 Jan 15;24(2):539-47. doi: 10.1016/j.bmcl.2013.12.026. Epub 2013 Dec 12.

PMID:
24365156
9.

Recent progress and challenges in the discovery of new neuraminidase inhibitors.

Chamni S, De-Eknamkul W.

Expert Opin Ther Pat. 2013 Apr;23(4):409-23. doi: 10.1517/13543776.2013.765861. Epub 2013 Feb 1. Review.

PMID:
23369206
10.

Structural and computational study on inhibitory compounds for endonuclease activity of influenza virus polymerase.

Fudo S, Yamamoto N, Nukaga M, Odagiri T, Tashiro M, Neya S, Hoshino T.

Bioorg Med Chem. 2015 Sep 1;23(17):5466-75. doi: 10.1016/j.bmc.2015.07.046. Epub 2015 Jul 29.

PMID:
26252962
11.

Identification of BPR3P0128 as an inhibitor of cap-snatching activities of influenza virus.

Hsu JT, Yeh JY, Lin TJ, Li ML, Wu MS, Hsieh CF, Chou YC, Tang WF, Lau KS, Hung HC, Fang MY, Ko S, Hsieh HP, Horng JT.

Antimicrob Agents Chemother. 2012 Feb;56(2):647-57. doi: 10.1128/AAC.00125-11. Epub 2011 Sep 19.

12.

Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease.

DuBois RM, Slavish PJ, Baughman BM, Yun MK, Bao J, Webby RJ, Webb TR, White SW.

PLoS Pathog. 2012;8(8):e1002830. doi: 10.1371/journal.ppat.1002830. Epub 2012 Aug 2.

13.

Strategies of development of antiviral agents directed against influenza virus replication.

Hsieh HP, Hsu JT.

Curr Pharm Des. 2007;13(34):3531-42. Review.

PMID:
18220789
14.

Identification of potential influenza virus endonuclease inhibitors through virtual screening based on the 3D-QSAR model.

Kim J, Lee C, Chong Y.

SAR QSAR Environ Res. 2009;20(1-2):103-18. doi: 10.1080/10629360902723962.

PMID:
19343586
15.

Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic.

Puzelli S, Facchini M, Di Martino A, Fabiani C, Lackenby A, Zambon M, Donatelli I.

Antiviral Res. 2011 Jun;90(3):205-12. doi: 10.1016/j.antiviral.2011.04.003. Epub 2011 Apr 14.

PMID:
21514326
16.

Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonuclease.

Stevaert A, Dallocchio R, Dessì A, Pala N, Rogolino D, Sechi M, Naesens L.

J Virol. 2013 Oct;87(19):10524-38. doi: 10.1128/JVI.00832-13. Epub 2013 Jul 3.

17.

Identification and characterization of influenza variants resistant to a viral endonuclease inhibitor.

Song MS, Kumar G, Shadrick WR, Zhou W, Jeevan T, Li Z, Slavish PJ, Fabrizio TP, Yoon SW, Webb TR, Webby RJ, White SW.

Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):3669-74. doi: 10.1073/pnas.1519772113. Epub 2016 Mar 14.

18.

Mutational and metal binding analysis of the endonuclease domain of the influenza virus polymerase PA subunit.

Crépin T, Dias A, Palencia A, Swale C, Cusack S, Ruigrok RW.

J Virol. 2010 Sep;84(18):9096-104. doi: 10.1128/JVI.00995-10. Epub 2010 Jun 30.

19.

Pyrazole compound BPR1P0034 with potent and selective anti-influenza virus activity.

Shih SR, Chu TY, Reddy GR, Tseng SN, Chen HL, Tang WF, Wu MS, Yeh JY, Chao YS, Hsu JT, Hsieh HP, Horng JT.

J Biomed Sci. 2010 Feb 23;17:13. doi: 10.1186/1423-0127-17-13.

20.

The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit.

Dias A, Bouvier D, Crépin T, McCarthy AA, Hart DJ, Baudin F, Cusack S, Ruigrok RW.

Nature. 2009 Apr 16;458(7240):914-8. doi: 10.1038/nature07745. Epub 2009 Feb 4.

PMID:
19194459
Items per page

Supplemental Content

Write to the Help Desk